Table 1.

Patient characteristics before and after SCIG use.

Case No.	Age sex	Antibody status A = AChRA, M = MUSK	Thymus	Thym- ectomy	MG therapy before SCIG	Concurrent MG therapy	No. of PLEX/year prior to starting SCIG	No. of PLEX/year after starting SCIG	MGFA score before SCIG	MGFA score after SCIG	MG-QOL-R score before SCIG	MG-QOL-R score after SCIG
1	45 F	A +	Hyperplasia	Yes	Mpred 8–24 mg/d, AZT 150 mg/d, Pyrido 300 mg/d	Mpred 2 mg/d, Pyrido 300 mg/d	5	0	19	9	27	18
2	47 F	A -, M -	No	No	Mpred 16–48 mg/d, Cy: 500 mg/month, Pyrido: 300 mg/d	Mpred 16 mg/d, MTX 15 mg/w, Pyrido: 300 mg/d	5	0	18	12	26	20

AChRA, acetylcholine receptor antibody; AZT, azathioprine; Cy, cyclophosphamide; MG, myasthenia gravis; MGFA, Myasthenia Gravis Foundation of America; MG-QOL-R, myasthenia gravis quality of life; Mpred, methylprednisolone; MTX, methotrexate; MUSK, Muscle-specific kinase antibody; No., number; PLEX, plasma exchange; Pyrido, pyridostigmine; SCIG, subcutaneous immunoglobulin.